Craft

Vita 34

Stock Price

€4.1

2024-10-29

Market Capitalization

€72.2 M

2024-10-29

Revenue

€88.2 M

FY, 2025

Vita 34 Summary

Company Summary

Overview
Since the foundation in 1997, the company has constantly advanced. Employees and management all share their belief in progress and innovation in stem cell therapy, which bears enormous medical potential. Vita 34 wants to participate actively in shaping this development. Experienced chemists, biologists, biotechnologists, specialized physicians and professional medical/technical assistants have made Vita 34 into that what it is today – the German specialist for stem cells from umbilical cord blood and tissue. For almost 20 years we have not only been storing umbilical cord blood, rather we have set standards with our experience, research and innovations, far beyond the borders of Germany.
Type
Public
Status
Active
Founded
1997
HQ
Leipzig, DE | view all locations
Website
https://www.vita34.de/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Frank Köhler, Chairman of the Supervisory Board

    • Florian Schuhbauer, Chairman of the Supervisory Board

      LocationsView all

      2 locations detected

      • Leipzig, Sachsen HQ

        Germany

        5A Deutscher Pl.

      • Leipzig, SN

        Germany

        Perlickstraße 5

      Vita 34 Financials

      Summary Financials

      Revenue (Q1, 2026)
      €21.5M
      Gross profit (Q1, 2026)
      €15.2M
      Net income (Q1, 2026)
      (€219.0K)
      Cash (Q1, 2026)
      €13.8M
      EBIT (Q1, 2026)
      €655.0K
      Enterprise value
      $83.1M

      Footer menu